A member of PhRMA told STAT that Purdue Pharma, which made oxycontin and has come under intense scrutiny for its part in fueling the opioid crisis, cut ties with the lobbying group in October.
A Purdue Pharma spokesperson told STAT that the decision “does not reflect any substantive disagreement with PhRMA” and it does not have to do with the drugmaker’s role in the opioid crisis.
The split may be because Purdue Pharma can’t afford the membership fees, as it filed for bankruptcy in September. The lobbying group has expensive membership fees and also requires members to spend at least $200 million each year on research and development, according to STAT.
Lobbyists were reportedly surprised Purdue Pharma left the group, and several told STAT they were unaware Purdue Pharma had left.
Read the full article here.
More articles on pharmacy:
Humana to buy hospice pharmacy Enclara Healthcare
Kite Pharma ordered to pay Juno Therapeutics $752M in CAR-T drug infringement case
Walgreens is Dow’s worst-performing stock of 2019
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
